摘要
                
                    miRNA是一组内源性非编码小RNA,广泛存在于真核生物中,已被表征为多种恶性肿瘤中基因表达和信号通路转导的关键调节因子。miR-142作为miRNA的一员,在多种恶性肿瘤中异常表达;其中,miR-142-3p和miR-142-5p在许多恶性肿瘤的发生以及肿瘤细胞的增殖、侵袭和转移中发挥关键作用。不同肿瘤患者体内miR-142的表达水平不同。因此,miR-142有望成为肿瘤早筛、诊断、治疗以及预后预测的新型生物靶点,发挥不可替代的作用。
                
                miRNAs are a group of endogenous non-coding small RNAs that are widely present in eukaryotes and have been characterized as key regulators of gene expression and signal pathway transduction in a variety of malignant tumors.As a member of miRNA,miR-142 is abnormally expressed in a variety of malignant tumors;among them,miR-142-3p and miR-142-5p play a key role in the occurrence,proliferation,invasion and metastasis of many malignant tumors.The expression level of miR-142 in patients with different tumors is different.Therefore,miR-142 is expected to become a new biological target for early tumor screening,diagnosis,treatment,and prognosis,and will play an irreplaceable role in the field of tumors.
    
    
                作者
                    杨宏平
                    李高峰
                    王书廷
                    马丽
                    张飞越
                    梁海峰
                YANG Hongping;LI Gaofeng;WANG Shuting;MA Li;ZHANG Feiyue;LIANG Haifeng(Second Department of Thoracic Surgery,The Third Affiliated Hospital of Kunming Medical University,Kunming 650118,Yunnan Province,China;Department of Oncology,The Fifth Affiliated Hospital of Kunming Medical University,Kunming 661000,Yunnan Province,China)
     
    
    
                出处
                
                    《肿瘤》
                        
                                CAS
                                CSCD
                                北大核心
                        
                    
                        2022年第9期658-666,共9页
                    
                
                    Tumor
     
            
                基金
                    国家自然科学基金(81760554)
                    云南省万人计划“名医”专项(C20096)
                    云南省卫生委员会医学领军人才培养计划(L-2019028)
            
    
    
    
                作者简介
Correspondence to:梁海峰,E-mail:lhf0671@126.com